CX3CR1
CX3C chemokine receptor1; GPR13; fractalkine receptor
CX3C chemokine receptor1 (CX3CR1), also known as the fractalkine receptor or GPR13, is the specific receptor to the CX3CL1. As the name suggests, CX3CR1 binds the chemokine CX3CL1 (also called fractalkine (in humans) or neurotactin (in mouse) ). CX3CL1 is a member of the CX3C family and that has been detected on activated endothelial cells, smooth muscle cells (SMCs), macrophages and platelets. CX3CL1 is the only neuronal chemokine in the body with pro-inflammatory, anti-inflammatory and neuroprotective effects, and is involved in the development of numerous inflammatory pathologies including atherosclerosis, rheumatoid arthritis, or graft rejection.
All Product Categories
-
CX3CR1 Produits associés (11)
Produits associés (11)
- 1
-
Alirocumab
0 ImagesCat. No.: HY-P9928CAS No.: 1245916-14-6Synonyms: REGN 727; SAR 236553Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation.
-
Alirocumab (anti-PCSK9)
0 ImagesSynonyms: REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation.
-
E6130
0 ImagesE6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.
-
AZD0233
0 ImagesAZD0233 is an orally active CX3CR1 antagonist. AZD0233 modulates the CX3CR1/CX3CL1 signaling axis via immunomodulatory effects. AZD0233 has improved physicochemical properties, metabolic stability, low toxicity and CYP inhibition. AZD0233 improves cardiac function and reduces macrophages and fibrotic scar in mice model of dilated cardiomyopathy. AZD0233 can be used for cardiovascular diseases like dilated cardiomyopathy research.
-
Fosrugocrixan
0 ImagesCat. No.: HY-168975CAS No.: 2408145-38-8Fosrugocrixan is an antagonist for CX3C chemokine receptor 1 (CX3CR1) that exhibits anti-inflammatory activity.
-
JMS-17-2 hydrochloride
0 ImagesCat. No.: HY-123918ACAS No.: 2341841-07-2
-
CX3CR1-IN-2
0 ImagesCat. No.: HY-181016CAS No.: 3105688-14-7CX3CR1-IN-2 (Compound 77) is a CX3CR1 inhibitor with an IC50 of 0.04 μM. CX3CR1-IN-2 can block the interaction between CX3CR1 and its ligand fractalkine (CX3CL1). CX3CR1-IN-2 can be used for research of cardiovascular disease, such as heart failure and cardiomyopathy .
-
CX3CR1-IN-1
0 ImagesCat. No.: HY-179653CAS No.: 3105117-66-3CX3CR1-IN-1 (Compound 24) is a CX3CR1 inhibitor with an IC50 of 9 nM. CX3CR1-IN-1 can be used for the study of cardiovascular diseases.
-
E6130 (Standard)
0 ImagesCat. No.: HY-107456RCAS No.: 1427058-33-0
- 1
